Palvella Therapeutics
Clinical-stage biotechnology company developing novel topical therapies for rare and serious dermatological conditions with high unmet medical need.
Website
https://www.palvellatx.comLocation
Wayne, Pennsylvania, USA
Founded
2017
Categories
biotech, dermatology, rare-diseases, topical-therapeutics
Notes
Palvella Therapeutics is a clinical-stage biotechnology company focused on developing novel topical therapies for rare and serious skin diseases. The company's lead program targets pachyonychia congenita (PC), a rare genetic skin disorder, and other dermatological conditions with significant unmet need.
Palvella's approach leverages proprietary drug delivery technology to enable effective topical treatments for conditions that currently lack adequate therapies.
Team
- J. Kevin Buchi - Chief Executive Officer
- James C. Loughner - Chief Financial Officer
Additional Research Findings
- Founded in 2017 in Wayne, Pennsylvania
- Portfolio company of BioAdvance
- Lead program QTORIN for pachyonychia congenita
- Focus on rare dermatological conditions
- Proprietary topical drug delivery platform
- FDA Orphan Drug and Fast Track designations
- Addressing conditions with no approved treatments